Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer



Status:Recruiting
Conditions:Postmenopausal Syndrome, Women's Studies, Hematology
Therapuetic Areas:Endocrinology, Hematology, Reproductive
Healthy:No
Age Range:50 - Any
Updated:4/5/2019
Start Date:November 15, 2017
End Date:January 1, 2020

Use our guide to learn which trials are right for you!

Pilot Study of Daily Exemestane in Women With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Grade 1 Endometrial Cancer

This pilot phase IIa trial studies how well exemestane works in treating patients with
complex atypical hyperplasia of the endometrium/endometrial intraepithelial neoplasia or low
grade endometrial cancer. Exemestane may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth.

PRIMARY OBJECTIVES:

I. To determine if there is a decrease in proliferation index, measured by Ki-67 expression,
in complex atypical hyperplasia (CAH)/endometrial intraepithelial neoplasia (EIN) or low
grade (grade 1 and grade 2) endometrial cancer cells from baseline to post-exemestane
treatment.

SECONDARY OBJECTIVES:

I. Circulating serum estradiol and progesterone. II. Pathological response (regression of
CAH/EIN or low grade [grade 1 and grade 2] endometrial carcinoma).

III. Tissue biomarkers. IV. Deoxyribonucleic acid (DNA) mutational analysis through next
generation sequencing and methylation status of endometrial tumor.

V. Protein markers via tampon recovery before and after treatment. VI. DNA markers via tampon
recovery. VII. Safety and adverse effects of treatment. VIII. Comparison of Ki-67 expression
changes between study subjects and a historical cohort.

IX. Evaluation of the levels of exemestane in the plasma samples pre and post treatment.

OUTLINE:

Patients receive exemestane orally (PO) once daily (QD) over 21-42 days in the absence of
disease progression or unaccepted toxicity. Patients undergo standard of care surgery between
days 22-43.

After completion of study treatment, patients with unresolved adverse events on day of
surgery are followed up periodically.

Inclusion Criteria:

- Females with a histologically proven CAH/ EIN or low grade (grade 1 or grade 2)
endometrial carcinoma (EC) for which surgery is planned; the pathologic report from
the referring facility will be used to determine pathologic eligibility; this report
must be within 45 days of their baseline (pre-surgical) clinic visit

- No prior treatment for CAH/EIN/EC

- Post-menopausal (>= 60 years of age or with follicle stimulating hormone [FSH] > 30
IU/L if age 50-59); the Ki-67 expression changes based on menopausal status and
specifically varies based on what phase of the menstrual cycle the sample is
collected; therefore, in order to eliminate this source of variability, only
postmenopausal women will be included in this trial. In addition, exemestane is
currently Food and Drug Administration (FDA) approved for use in post-menopausal women
only

- Eastern Cooperative Oncology Group (ECOG) performance status =< 1

- Hemoglobin >= 9 g/dL

- Serum creatinine =< 1.5 x upper limit of normal or calculated creatinine clearance >=
60 mL/min using Cockcroft-Gault equation for patients with creatinine levels > 1.5 x
institutional upper limit of normal (ULN)

- Total bilirubin =< 1.5 x ULN OR direct bilirubin =< 1 x ULN

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN

- White blood cell (WBC) >= 3000/mcl

- Platelets >= 100,000/mcl

- Able and willing to take oral medications

- Ability to understand and the willingness to sign a written informed consent document

- Body mass index (BMI) > 20

Exclusion Criteria:

- Participants who had curatively treated invasive malignancies for which all treatments
ended within 1 year prior to the study (with the exception of basal cell or squamous
cell carcinoma of the skin)

- Not a surgical candidate or surgery is not scheduled within 43 days from starting the
study drug

- Receiving any other investigational agents

- Any gastrointestinal condition causing malabsorption or obstruction (e.g. celiac
sprue, gastric bypass surgery, strictures, adhesions, history of small bowel
resection, blind loop syndrome)

- Has been on any hormonal treatment (including progestin-containing intrauterine device
[IUD]) for CAH/EIN or low grade (grade 1 or grade 2) endometrial carcinoma in last 3
months

- Use hormone replacement therapy (including systemic or topical estrogen, progesterone,
or testosterone based medication) or/and phytoestrogen supplements (i.e. black cohosh)
or has been on progestin (including progestin containing IUD), tamoxifen or aromatase
inhibitor within the prior 3 months

- Concomitant use of strong CYP3A4 inducers such as rifampicin, phenytoin,
carbamazepine, phenobarbital or St. John's wort as these may significantly reduce the
availability of exemestane

- Known hypersensitivity to exemestane or its excipients

- Known intercurrent illness or psychiatric illness/social situations that will limit
compliance with study requirements

- Evidence or high suspicion of metastatic disease at enrollment

- Women with severe bone density issues/osteoporosis (defined as any medical treatment
for osteoporosis, and/or a T-score of -2.5 or lower, and/or history of fracture of the
hip or spine)

- Unwilling or unable to undergo research biopsy during the baseline (pre-surgical)
clinic visit, or inadequate research biopsy obtained during the baseline
(pre-surgical) clinic visit (determined by the gynecologic oncologist at the time of
the subject's pelvic exam)
We found this trial at
3
sites
Birmingham, Alabama 35233
Principal Investigator: Rebecca C. Arend
Phone: 205-934-4986
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
600 Highland Ave
Madison, Wisconsin 53792
(608) 263-6400
Principal Investigator: Howard H. Bailey
Phone: 608-263-8624
University of Wisconsin Hospital and Clinics UW Health strives to meet the health needs of...
?
mi
from
Madison, WI
Click here to add this to my saved trials
Minneapolis, Minnesota 55455
Principal Investigator: Britt K. Erickson
Phone: 612-626-6283
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials